**Sir**,

We congratulate the authors on performing this multicentre trial with 164 patients ([@bib2]). One important selection criterion is the initial size of the primary tumor (T size) on imaging -- this information did not appear in the manuscript and is of interest. The probability of adequately sampling the initial region of disease by image guidance is likely related to the T size at diagnosis and the size of residual disease on imaging. Do the authors have information on the initial T stage of all patients and the size of residual imaging abnormality at the time of pre-surgical biopsy? This is not the first report regarding the concept of minimally invasive techniques for sampling to assess pathologic complete response in breast cancer ([@bib1]). The success of moving these studies into the realm of clinical omission of surgery is dependent on exquisite radiologic targeting of the lesion (37% did not have a clip placed at initial biopsy in the current study), adequate sampling with vacuum-assisted biopsy (utilized in the current study in ∼30%), and the number of biopsies performed (unknown 55% of cases). At MD Anderson, we have an actively accruing trial using image-guided vacuum-assisted biopsy with fine-needle aspiration and more stringent selection criteria including patients with a 50--70% chance of pathologic eradication of disease after neoadjuvant chemo- and targeted therapy (triple-negative and HER2-amplified breast cancers) ([@bib3]).
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